icon-folder.gif   Conference Reports for NATAP  
  The Liver Meeting
Digital Experience
Washington on 04-08
November 2022
Back grey_arrow_rt.gif
HCC Risk in HCV After SVR in Cirrhosis or No Cirrhosis
  Post HCV DAA Treatment Cure HCC Surveillance is NOT BEING DONE & likely contributes significantly to HCC. Jules Levin, NATAP
AASLD: Hepatocellular Carcinoma: State of the Art - missing is & Post HCV Cure Surveillance in Patients with Cirrhosis ! - (11/21/22)
we see a rising mortality rate in men & women, one of the few cancers in which we see this. If these trends continue HCC is projected to be 3rd leading cause of death by 2035.


AASLD: Risk factor of hepatocellular carcinoma occurrence after sustained virologic responses in hepatitis C virus patients without advanced liver fibrosis - (11/14/22)
AASLD: The impact of direct-acting antiviral treatment for HCV on hepatocellular carcinoma risk in a large population-based cohort study - (11/17/22)


AASLD: Increasing time since eradication of HCV is independently associated with a lower risk of HCC - (11/09/22)


AASLD: 67% Remain Untreated - Burden of Illness Associated with Remaining Untreated Following a Diagnosis of Chronic Hepatitis C Virus - (11/08/22)